fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon’s first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and...
– Patent will further expand intellectual property protection for MYDICAR® – a first in class drug under clinical evaluation for advanced heart failure   Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent...
Investment to Advance ColoAd1 through Phase II Clinical Trial for Colorectal and Other Forms of Cancer PsiOxus Therapeutics, Ltd. (PsiOxus) announced that it has closed a Series B round of equity financing totaling £22 million ($34 million). The round included equal investments from existing investors Imperial Innovations Group (AIM: IVO, ‘Innovations’) and Invesco Perpetual together...
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the appointment of Mr. Offer Nonhoff as Chief Financial Officer. Mr. Nonhoff replaces Mr. Fredrik Groth who is leaving the Company to pursue new challenges. Mr. Nonhoff comes to BONESUPPORT from Lumenis, a...
  BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, reported today that it received SEK 70M; $9.9M; euro 8M in cash within the second and final tranche of funding. This is part of a larger investment that was announced in June 2011 when the...
  Promising safety and efficacy interim clinical results after 6 months of treatment in peanut-allergic children using Viaskin® Peanut presented at the European Academy of Allergy and Clinical Immunology EAACI ARACHILD Study is currently still ongoing DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy,...
Patent will expand intellectual property protection for MYDICAR – a first in class drug under clinical evaluation for advanced heart failure Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has received a Notice of Allowance from the European Patent Office (EPO) for...
  NBS System now available to US patients for both motor and speech mapping of the cortex Helsinki, Finland — Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the NexSpeech® module for use with the Navigated Brain Stimulation (NBS) System. In presurgical planning for patients with...
Additional Presentations at ATC Will Provide Supporting Evidence of the Activity and Tolerability of LCP-Tacro in Kidney and Liver Transplant Patients   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely...
1 62 63 64 65 66 69

Lundbeckfonden Ventures

Nyheder

LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
7. januar 2021
Acacia – Admission to Trading on Euronext Brussels
18. december 2020
Acacia – Publication of Supplementary Prospectus
17. december 2020